Retatrutide

Retatrutide, also known as LY3437943 TFA, is an advanced peptide designed to activate three key metabolic receptors at once: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R). By engaging all three pathways, retatrutide delivers a broad metabolic response that goes beyond what single or dual agonists can achieve. In receptor activity testing, it has shown strong potency, with EC50 values of 5.79 nM for GCGR, 0.0643 nM for GIPR, and 0.775 nM for GLP-1R.

Retatrutide is being studied mainly for its role in obesity research, where it has produced notable reductions in body weight. Its benefits are not limited to weight management, though. Clinical findings show meaningful improvements in blood sugar control, with a large proportion of participants reverting from prediabetes back to normal glucose levels. Additional data point to positive cardiovascular effects, including reductions in both systolic and diastolic blood pressure, along with healthier lipid markers. These combined outcomes position retatrutide as a promising multi-target peptide for metabolic and cardiometabolic research. Para Pharma Montana